EMBA COURSES FOR HEALTH SECTOR MANAGEMENT
HSM course requirements can be completed in conjunction with MBA core work or post-graduation. Scheduling courses is determined by student preferences and goals, and subject to course availability.
Course Descriptions
HLTHMGMT 710 – Health Institutions, Systems, and Policy (HSM Bootcamp)
This intensive 4-day course offers HSM students an in-depth overview of the interconnected sectors within the healthcare industry, such as physicians, hospitals, payers, and pharmaceutical and medical device companies. The class is open to both Daytime and EMBA HSM students, who can attend in person at Fuqua or participate virtually via Zoom (with special permissions).
HLTHMGMT 705E – 707E Fundamentals of Health Sector Management (HSM Seminar)
The Fundamentals of HSM: A Global Perspective is a multi-term seminar course that addresses key challenges in the value chain by which people and organizations around the world create, deliver, and consume health care goods and services. This course is delivered via Zoom, one Sunday each month for six months. The course concludes with a half-day in-person conference that coincides with the start of the Elective Term 1.
HLTHMGMT 897E – HSM Project Course
The HSM Project Course is an in-depth analysis of a healthcare challenge or opportunity with actionable recommendations. Students work with a project advisor to refine the project and then carry out the research needed to complete the analysis.
HSM Certificate + MBA Concentration: The Duke MBA Concentration “Capstone” Project must be completed FIRST. The HSM Project Course would then be completed the year after the Concentration Project is completed and the HSM Certificate would be awarded at the end of that term.
HLTHMGMT 711E – Health Care Markets: This course applies the tools of economics and strategy to the challenges and opportunities faced by product manufacturers, insurers, health care providers, and others in the health sector.
HLTHMGMT 718E – Life Science Strategy: Examine product strategy in the biotech, device, and pharmaceutical industries. Consider the perspectives of large incumbents, entrepreneurial start-ups, and companies in between. Life science product companies face new challenges and opportunities in a business environment characterized by rapid growth in emerging markets, but increasing regulatory oversight and reimbursement challenges in the developed markets.